A Mini Review of Novel Topoisomerase II Inhibitors as Future Anticancer Agents

[First Article published in 2023, Impact Factor 6.208]

Several reviews of inhibitors of topoisomerase II have been published, covering research before 2018. Therefore, this review is focused primarily on more recent publications with relevant points from the earlier literature

https://www.mdpi.com/1422-0067/24/3/2532/

https://www.mdpi.com/1422-0067/24/3/2532

Unknown's avatar

Author: Toluwase Fatoki Center

Toluwase Fatoki is a training and consulting business entity involving in leading research in applied bioinformatics, biomarketing and principled leadership.